BSECompany Update3d ago · 4 Aug 2026, 12:34 pm

Transcript of Conference call with Analysts / Investors on Financial Results for the quarter ended 30th June, 2026

Torrent Pharmaceuticals Ltd · 500420

✦ AI SummaryResults

Torrent Pharmaceuticals Ltd has released the transcript of its conference call with analysts and investors regarding its financial results for the quarter ended 30th June, 2026. The transcript is available on the company's website.

Analysis Scores

Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk2/10
Liquidity Impact8/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Torrent Pharmaceuticals Ltd - 500420 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

Attachments (1)

📄

675e9770-7b12-4c67-bbdd-29ddb3303c7f.pdf

pdf

Download →
View document text
04th August, 2026 The Dy. General Manager (Listing Dept.) The Manager – Listing Dept., BSE Limited, National Stock Exchange of India Ltd., Corporate Relationship Dept., Exchange Plaza, 5th Floor, 1st Floor, New Trading Ring, Plot No. C/1, G. Block, P. J. Towers, Dalal Street, Fort, Bandra - Kurla Complex, Bandra (E), Mumbai - 400 001 Mumbai – 400 051 (BSE Scrip Code: 500420) (NSE Scrip Code: TORNTPHARM) Dear Sir, Sub.: Transcript of Conference call with Analysts / Investors on Financial Results for the quarter ended 30th June, 2026 In continuation of our letter dated 17th July, 2026 and pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Transcript of Conference call with Analysts / Investors on Financial Results of the Company for the quarter ended 30th June, 2026, has been placed on the Company’s website at https://torrentpharma.com/pdf/investors/Q1-FY26-27_Earnings-Call-Transcript.pdf Kindly take note of the above. Thanking you, Yours Sincerely, For TORRENT PHARMACEUTICALS LIMITED CHINTAN M. TRIVEDI COMPANY SECRETARY Email – investorservices@torrentpharma.com